# A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

> **NCT03827200** · PHASE2 · TERMINATED · sponsor: **Noorik Biopharmaceuticals AG** · enrollment: 19 (actual)

## Conditions studied

- Cirrhosis
- Portal Hypertension
- Ascites

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT03827200
- **Lead sponsor:** Noorik Biopharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-11
- **Primary completion:** 2020-12-29
- **Final completion:** 2021-01-21
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Lack of recruitment, result of COVID-19 pandemic
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827200, "A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03827200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*